Luigi Md Lenaz Net Worth

The estimated Net Worth of Luigi Md Lenaz is at least $112 mil dollars as of 22 May 2018. Luigi Lenaz owns over 40,000 units of Spectrum Pharmaceuticals stock worth over $112,349 and over the last 21 years Luigi sold SPPI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Luigi Lenaz SPPI stock SEC Form 4 insiders trading

Luigi has made over 1 trades of the Spectrum Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently Luigi exercised 40,000 units of SPPI stock worth $58,800 on 22 May 2018.

The largest trade Luigi's ever made was exercising 40,000 units of Spectrum Pharmaceuticals stock on 22 May 2018 worth over $58,800. On average, Luigi trades about 1,212 units every 0 days since 2003. As of 22 May 2018 Luigi still owns at least 109,077 units of Spectrum Pharmaceuticals stock.

You can see the complete history of Luigi Lenaz stock trades at the bottom of the page.

What's Luigi Lenaz's mailing address?

Luigi's mailing address filed with the SEC is C/O SPECTRUM PHARMACEUTICALS, INC., 157 TECHNOLOGY DRIVE, IRVINE, CA, 92618.

Insiders trading at Spectrum Pharmaceuticals

Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, eThomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.

What does Spectrum Pharmaceuticals do?

spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Complete history of Luigi Lenaz stock trades at Spectrum Pharmaceuticals

Spectrum Pharmaceuticals executives and stock owners

Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Turgeon,
  President, Chief Executive Officer, Director
• Thomas Riga,
  Chief Operating Officer, Chief Commercial Officer, Executive Vice President
• Kurt Gustafson,
  Chief Financial Officer, Executive Vice President
• Keith McGahan,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Francois Lebel,
  Executive Vice President, Chief Medical Officer
• Thomas J. Riga,
  Pres, CEO & Director
• Kurt A. Gustafson,
  Exec. VP & CFO
• Dr. Francois J. Lebel FRCPC, M.D.,
  Exec. VP & Chief Medical Officer
• Keith M. McGahan J.D., L.L.M.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• William Ashton,
  Independent Chairman of the Board
• Bernice Welles,
  Independent Director
• Jeffrey Vacirca,
  Independent Director
• Dolatrai Vyas,
  Independent Director
• Elizabeth Czerepak,
  Independent Director
• Seth Fischer,
  Independent Director
• Lyndah Dreiling,
  Senior Vice President, Clinical Development
• Dr. Lyndah K. Dreiling M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Lisa A. Croissant,
  VP of Sales
• Alberto Dejesus,
  VP of Marketing
• Bimal R. Shah,
  VP of Corp. & Bus. Devel.
• Anthony E Iii Maida,
  Director
• Raymond W Cohen,
  Director
• Stuart Mitchell Krassner,
  Director
• Gilles Gagnon,
  Director
• Luigi Md Lenaz,
  President, Oncology Division
• Juhyun Lim,
  Director
• Jeff L Vacirca,
  Director
• Ann C Phd Kessler,
  Director
• Armin M Kessler,
  Director
• Lee F Md Ph D Allen,
  Chief Medical Officer
• Joseph Kenneth Keller,
  EVP & Chief Operating Officer
• Carol Phd Ocleireacain,
  Director
• Paul H Phd Silverman,
  Director
• Shyam K Kumaria,
  Vice President Finance
• Mark J Glasky,
  Director
• Krishan K Arora,
  Director
• Eric L Phd Nelson,
  Director
• John L Mcmanus,
  VP,Finance, Strategic Planning
• Rajesh C Md Shrotriya,
  Ch, Pres. and Chief Exec. Off.
• Julius A Vida,
  Director
• Dilip J Md Phd Mehta,
  Director
• Richard Fulmer,
  Director
• James Shields,
  Chief Commercial Officer
• Brett L Scott,
  Acting Chief Financial Officer
• Anton Gueth,
  Director
• Mitchell P. Cybulski,
  Director
• George F Tidmarsh,
  CSO AND HEAD OF R&D OPERATIONS
• Nora Brennan,
  See Remarks